Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated whole virion vero cell-derived influenza vaccine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated whole virion Vero cell-derived influenza vaccine is a biologic vaccine platform developed by Baxter AG. Unlike traditional influenza vaccines produced in embryonated chicken eggs, this vaccine is manufactured using Baxter's proprietary Vero cell technology, a continuous mammalian cell line. This method allows for a more rapid scale-up during pandemics and avoids the risk of egg-protein allergies. The vaccine contains the entire inactivated influenza virus, preserving all viral surface antigens, including hemagglutinin (HA) and neuraminidase (NA), which stimulates a broad immune response. It has been formulated as a monovalent vaccine for pandemic strains (e.g., H5N1, branded as Vepacel; H1N1, branded as Celvapan) and as a trivalent vaccine for seasonal influenza.
- Brand names
- VepacelCelvapan
- Other names
- Vero cell-derived whole virion influenza vaccineBaxter Vero cell influenza vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)N1 NA (Influenza A neuraminidase N1)T-cell receptor specific for influenza H5N1 peptide–major histocompatibility complexB-cell receptor specific for influenza H5N1 antigensTLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on inactivated whole virion vero cell-derived influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated whole virion vero cell-derived influenza vaccine.